1 **Population Pharmacokinetics of an Anti-PD-1 Antibody**

2 **Camrelizumab in Patients with Multiple tumor types and model**

3 **informed dosing strategy**

4 Chen-yu Wang^{a, #}; Chang-cheng Sheng^{b, #}; Guang-li Ma^c; Da Xu^c; Xiao-qin Liu^d;
 5 Yu-ya Wang^c; Li Zhang^e; Chuan-liang Cui^f; Bing-he Xu^g; Yu-qin Song^h, Jun Zhu^h;
 6 Zheng Jiao^{a*}

7 a Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University,
 8 Shanghai, P.R.China.

9 b Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang,
 10 P.R.China.

11 c Department of Clinical Pharmacology, Jiangsu Hengrui Medicine Co. Ltd, Shanghai,
 12 P.R.China

13 d Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, P.R.China

14 e Department of Medical Oncology; Sun Yat-sen University Cancer Center,
 15 Guangzhou, P.R.China

16 f Key Laboratory of Carcinogenesis and Translational Research (Ministry of
 17 Education/Beijing), Department of Renal Cancer and Melanoma, Peking University
 18 Cancer Hospital & Institute, Beijing, P.R.China.

19 g Department of Medical Oncology, National Cancer Hospital, Chinese Academy of
 20 Medical Sciences, Beijing, P.R.China.

21 h Key Laboratory of Carcinogenesis and Translational Research (Ministry of
 22 Education), Department of Lymphoma, Peking University Cancer Hospital & Institute,
 23 Beijing, China.

24

25 # Chen-yu Wang and Chang-cheng Sheng made equal contributions to this work.

26

27

28 ***Corresponding author:**

29 Zheng Jiao, Professor

30 Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University

31 241 Huaihai West Road, Shanghai, China, 200030

32 Tel.: +86 (21) 2220 0000 ext 3021

33 E-mail: jiaozhen@online.sh.cn;

34 ORCID: 0000-0001-7999-7162

35

36 **Abbreviations:** AIC, Akaike's information criterion; AUC, area under the
 37 concentration-time curve; AUC_{ss}, steady-state area under the concentration-time curve;
 38 BSV, Between-subject variability; C, camrelizumab concentration; C₁, concentration
 39 of central compartment; C_{average,ss}, steady-state average concentration; CL, clearance;
 40 CL_{linear}, clearance of linear elimination; C_{max,ss}, steady-state peak concentration;
 41 CL_{nonlinear}, clearance of nonlinear elimination; C_{min,ss}, steady-state trough
 42 concentration; CWRES, conditional weighted residuals; DV, observed concentration;
 43 IPRED, individual predicted concentrations; k₀, infusion rate; k₂₃, elimination rate
 44 from central compartment to peripheral compartment; k₃₂, elimination rate from
 45 peripheral compartment to central compartment; k_{linear}, linear elimination rate;
 46 k_{nonlinear}, nonlinear elimination rate; K_m, Michaelis–Menten constant; mAb,
 47 monoclonal antibody; NONMEM, nonlinear mixed effect modeling; PD-1,
 48 programmed cell death 1 receptor; PK, pharmacokinetics; PRED, population
 49 predicted concentration; Q, inter-compartmental clearance; Q2W, every 2 weeks; V_m,
 50 maximum elimination rate; VPC, visual predictive check; V₁, distribution volume of
 51 central compartment; V₂, distribution volume of peripheral compartment; WBC,
 52 white blood cell.

54 Abstract

55 **Objective:** Camrelizumab, a programmed cell death 1 (PD-1) inhibitor, has been
56 approved for the treatment of relapsed or refractory classical Hodgkin lymphoma. The
57 aim of this study was to perform a population pharmacokinetics (PK) analysis of
58 camrelizumab to quantify the impact of patient characteristics on PK and to
59 investigate the appropriateness of flat dose in the dosing regimen.

60 **Methods:** A total of 3298 camrelizumab concentrations from 133 patients from four
61 studies were analyzed using nonlinear mixed effects modeling. Covariate model
62 building was conducted using stepwise forward addition and backward elimination.
63 Monte Carlo simulation was conducted to compare exposures of 200 mg and 3 mg/kg
64 every 2-week regimens.

65 **Results:** The PK of camrelizumab were adequately described by a two-compartment
66 model with parallel linear and nonlinear clearances. Baseline albumin had significant
67 effects on linear clearance, and weight had effects on inter-compartmental clearance.
68 Moreover, 200 mg and 3 mg/kg regimens provide similar exposure distributions with
69 no advantage to either dosing approach.

70 **Conclusion:** Population PK analysis provided an integrated evaluation of the impact
71 of albumin and weight on the PK of camrelizumab. It also provided evidence that
72 neither the flat-dose nor the weight-based dose regimen was advantageous over the
73 other for most patients with tumors.

74
75 **Keywords:** Camrelizumab; Programmed cell death 1 inhibitor; population
76 pharmacokinetics; Monte Carlo simulation; dosing regimen

77

1 Introduction

The programmed cell death 1 (PD-1) pathway plays a critical role in maintaining an immunosuppressive tumor microenvironment, and blockade of the PD-1 pathway has become the key component of cancer immunotherapy.¹ Camrelizumab (SHR-1210, AiRuiKa™) is a humanized high-affinity IgG4-kappa monoclonal antibody (mAb) to PD-1.² In May 2019, the National Medical Products Administration of China approved camrelizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma.^{3, 4} Camrelizumab is also being investigated as a treatment for other various malignancies, including gastric/gastroesophageal junction cancer, hepatocellular carcinoma, and nasopharyngeal cancer.⁵⁻⁷

The pharmacokinetics (PK) characteristics of camrelizumab are consistent with other typical IgG4 antibodies.⁸ Non-compartmental analysis indicated a half-life of 3 – 11 days from 1 mg/kg to 10 mg/kg after a single dose. While C_{max} increased proportionally with dose from 1 mg/kg to 10 mg/kg, area under the concentration-time curve (AUC) increased in a supralinear manner over the same dose range.⁸ In phase I clinical studies of 60 to 400 mg infusions of camrelizumab, the coefficient of variation of AUC was more than 30%.⁹ Therefore, it is necessary to analyze the factors that affect PK properties of camrelizumab and to investigate the effect of these factors on dosing regimen.¹⁰

Early clinical studies of camrelizumab employed bodyweight-based dosing strategies of 1 mg/kg to 10 mg/kg every 2 weeks (Q2W) and compared 3 mg/kg with a flat-dose regimen of 200 mg Q2W. Although the flat-dose was selected for the subsequent expansion phase based on the PK and receptor occupancy data, the relevance of body weight to the exposure of camrelizumab has not been established. A dose adjustment of camrelizumab may be required when there is a large variation in the weight of patients.^{7, 11} Population PK analysis of data obtained in patients across multiple trials was the most efficient approach to answer this question.¹²

105 In this study, a population-PK model of camrelizumab was developed using
106 pooled data from four Phase I and Phase II clinical trials to evaluate the impact of
107 covariates on exposure, to support dose recommendations in subpopulations, and to
108 assess the adequacy of a weight-based dosing regimen.

109 **2 Methods**

110 **2.1 Population-pharmacokinetic Data**

111 Data from three phase I and one phase II clinical trials in patients with advanced
112 solid tumors, melanoma, or relapsed/refractory classical Hodgkin lymphoma were
113 pooled to conduct this population PK analysis ([Table 1](#)). A total of 133 patients were
114 enrolled in this analysis. The three phase 1 trials (SHR-1210-101, SHR-1210-102,
115 SHR-1210-103) and one phase 2 trial (SHR-1210-II-204) were registered at Chinese
116 Clinical Trial Registry (CTR20160175, CTR20160207, CTR20160248,
117 CTR20170500, respectively). All studies were carried out in accordance with
118 principles as defined in the Declaration of Helsinki (October 2013)¹³. The protocol
119 and all amendments were approved by the institutional review board and independent
120 ethics committee of each trial center. Informed consent was obtained from each
121 patient before enrollment.

122 For the assessment of camrelizumab PK, serum samples were collected at
123 prespecified time points in each of the studies. An intensive sampling strategy was
124 employed in the first cycle of the three phase 1 trials (SHR-1210-101, SHR-1210-102,
125 SHR-1210-103). Subsequent cycles of the phase 1 trials and all cycles of the phase 2
126 trial (SHR-1210-204) employed a sparse sampling strategy. The details of the study
127 design in each trial are listed in [Table 1](#).

128 Camrelizumab concentrations were measured by enzyme linked immunosorbent
129 assay using a calibration range of 157 - 10,000 ng/mL for the three phase 1 trials, and
130 180 - 10,000 ng/mL for the phase 2 trial.^{7,9}

131 Patients were defined as evaluable for PK analysis if they had ≥ 1 adequately

dose and ≥ 1 corresponding concentration sample. Covariates with data missing for $>10\%$ of the patients were not included in the analysis. The data of covariates with data missing for $\leq 10\%$ of the patients were imputed to the population median for continuous covariates and values with higher frequency for categorical covariates.

2.2 Population PK Analyses

Population PK models were developed using a nonlinear mixed effect modeling (NONMEM) approach, as implemented in the NONMEM software (version 7.4.0, ICON Development Solutions, Ellicott City, MD, USA) using first-order conditional estimation with interaction. Graphical and statistical analyses, including evaluation of NONMEM outputs, were performed with Perl speaks NONMEM (PsN, version 4.7.0, Department of Pharmaceutical Biosciences, Uppsala University, Sweden), R (version 3.4.1, R Foundation for Statistical Computing, Vienna, Austria), R packages Xpose (version 4.5.3, Department of Pharmaceutical Biosciences, Uppsala University, Sweden), and Pirana (version 2.9.7, Certara, Inc. Princeton, USA).

2.2.1 Base Model

In the development of the structural PK model, the concentration-time data were fitted to one- and two-compartment models with linear and nonlinear clearance ($CL_{\text{nonlinear}}$), and the suitability of the models was assessed. Nonlinear elimination pathways were explored by incorporating CL described by Michaelis–Menten kinetics¹⁴ (Eq. 1):

$$CL_{\text{nonlinear}} = \frac{V_m}{K_m + C} \quad (\text{Eq. 1})$$

where $CL_{\text{nonlinear}}$ is the nonlinear elimination rate, V_m is the maximum elimination rate, C is the camrelizumab concentration, and K_m is the Michaelis–Menten constant, the concentration at which 50% of the maximum elimination rate is reached.

Between-subject variability (BSV) was assumed to follow a log-normal distribution and was therefore implemented into the model as follows¹⁵ (Eq. 2):

$$P_i = P_{\text{pop}} \times e^{(\eta_i)} \quad (\text{Eq. 2})$$

where P_i depicts the individual or *post hoc* value of the parameter for the *i*th

individual, P_{pop} depicts the population mean for the parameter, and η_i depicts the empirical Bayes estimate of BSV for the i^{th} individual, sampled from a normal distribution with a mean of zero and a variance of ω^2 .

Residual error was evaluated as a proportional or additive error, or as a combination of both (Eq. 3).

$$Y = IPRED \times (1 + \varepsilon_{proportional}) + \varepsilon_{additive} \quad (\text{Eq. 3})$$

where Y is the observed concentration, $IPRED$ is the individual predicted concentration, $\varepsilon_{proportional}$ is the proportional error component, and $\varepsilon_{additive}$ is the additive error component. Residual error components are sampled from a normal distribution with a mean of zero and variance of σ^2 .

The base model selection was based on Akaike's information criterion (AIC)¹⁶, precision of parameter estimates, condition number, and goodness-of-fit plots.

2.2.2 Covariate model

A three-step approach was used for the covariate analysis. In the first step, the relationship between PK parameters and covariates was screened by plotting the individual empirical Bayes estimates for PK parameters versus potential covariates. This was followed by linear regression for continuous covariates and analysis of variance testing for categorical covariates. Only those covariates with a significant effect ($r > 0.2$, $p < 0.001$) on the estimated PK variables, which could be meaningfully explained from both a clinical and scientific perspective, were carried through to the next stage.

In the second step, the identified covariates were added to the base model one at a time. Significance was assessed using the likelihood ratio test, where the addition of one parameter required a reduction in objective function value > 3.84 ($p < 0.05$) obtained by NONMEM during the forward inclusion. All significant covariates were included in the full model and additional covariates of borderline significance were only included if the covariate was highly likely to be influential based on scientific judgment.

The final step involved a stepwise backward elimination process, starting with the full model and removing each covariate one at a time. The covariate that was the least significant was removed and the process was repeated. The criterion for retention of a covariate in the model was a change in likelihood ratio >6.63 for one parameter ($p < 0.01$) during the stepwise backward elimination stage.

Continuous covariates were evaluated using both a linear function and a power function (Eq. 4 and 5). Categorical covariates were tested using (Eq. 6):

$$P_i = \theta_1 \times \left(1 + \theta_2 \times \frac{Cov_i}{Cov_{median}} \right) \quad (\text{Eq. 4})$$

$$P_i = \theta_1 \times \left(\frac{Cov_i}{Cov_{median}} \right)^{\theta_2} \quad (\text{Eq. 5})$$

$$P_i = \theta_1 \times (1 + \theta_2^{Cov_i}) \quad (\text{Eq. 6})$$

where P_i and Cov_i are the parameter and covariate value for the i th individual, respectively, Cov_{median} is the median value for the covariate, θ_s are the parameters to be estimated, and θ_1 represents the typical value of a pharmacokinetic parameter in an individual with the median value for the covariate.

The shrinkage derived from the final model was assessed for each BSV term, as well as for residual variability.

2.3 Model evaluation

Goodness-of-fit plots were used for model evaluation including observed concentration (DV) vs. population predicted concentration (PRED), DV vs. individual predicted concentrations (IPRED), conditional weighted residuals (CWRES) vs. PRED, and CWRES vs. time.

The PK parameters were estimated repeatedly by fitting the final model to 1000 bootstrap datasets, sampled from the original dataset with replacement¹⁷. The median values and 2.5%~97.5% of the population PK parameter estimates from these 1000 bootstrap datasets were compared with the point estimates from the final model.

The predictive performance of the final model was assessed using a visual predictive check (VPC) approach, which compared the distribution of observed

concentrations and model predictions. A total of 1000 simulated datasets were generated using the final model.

2.4 Dosing regimen

Monte Carlo simulations, using the individual empirical Bayes PK parameters, were used to evaluate the effect of body weight on the PK of camrelizumab when administered at a dose of 200 mg Q2W and compared to the effects of a body weight-adjusted dose of 3 mg/kg Q2W.

To predict camrelizumab PK in each dosing regimen group, 1000 virtual patients were created by randomly drawing covariate values with replacement from the pooled modeling data.

BSV and residual variability in the model were sampled from the established distributions, together with PK parameters and covariate relationships for each virtual patient, which were in turn used to determine steady-state peak concentration ($C_{\max,ss}$), steady-state trough concentration ($C_{\min,ss}$), steady-state average concentration ($C_{\text{average},ss}$), and steady-state AUC (AUC_{ss}). $C_{\text{average},ss}$ was calculated as (Eq. 7):

$$C_{\text{average},ss} = \frac{AUC_{ss}(mg \times weeks/L)}{\text{dosing interval (weeks)}} \quad (\text{Eq. 7})$$

where $C_{\max,ss}$ and $C_{\min,ss}$ were determined from the concentration-time profile using each individual's *pos-hoc* estimated pharmacokinetic parameters. AUC_{ss} is AUC in one dosing interval at steady state. Summary statistics (median, 5% – 95%) were determined using R software.

236 **3 Results**

237 **3.1 Demographics**

238 The dataset included 133 patients who provided a total of 3298 plasma
239 concentrations, of which 206 samples were excluded: 203 (6.16%) samples below the
240 limit of quantification and 3 (0.09%) samples with missed values. For covariates, no
241 data were missing. In total, 3092 observations (93.75%) were used in the population
242 PK analysis. A summary of patient demographics for the analysis dataset is presented
243 in [Table 2](#). The patients presented various tumor types, and two-third of the patients
244 were male.

245 **3.2 Population Pharmacokinetic Model**

246 **3.2.1 Base Model**

247 Two compartment models were found to better describe the camrelizumab
248 pharmacokinetics than the one compartment model, resulting in a decrease of >300
249 points in AIC. Inclusion of first order and nonlinear elimination resulted in a further
250 decrease in AIC of 60 points compared with the linear model. The model was
251 parameterized by clearance of linear elimination (CL_{linear}), inter-compartmental
252 clearance (Q), distribution volume of central compartment (V_1), distribution volume
253 of peripheral compartment (V_2), V_m and K_m . The model structure is shown in [Figure](#)
254 [1](#).

255 BSV was estimated for CL_{linear} , V_1 , and V_m for the acceptable precision of
256 parameter estimates. The residual error was best described by a combined
257 proportional and additive error model.

258 **3.2.2 Covariate Model**

259 The covariates investigated included baseline age, weight, sex, race, creatinine
260 clearance, aspartate aminotransferase, alanine aminotransferase, total bilirubin,
261 albumin, hemoglobin, platelet count, and white blood cell (WBC) count. Initial
262 graphical screening showed significant effects of albumin, hemoglobin, platelets, and
263 WBC on CL_{linear} , weight on V_1 , and weight on Q ($r > 0.2$, $p < 0.001$). When these

covariates were tested in a forward inclusion step, the effects of albumin, platelets, WBCs, and weight were significant ($p < 0.05$) and retained in the model. The effects of WBCs and platelets on CL_{linear} , and weight on V_1 , were excluded using a stepwise backward elimination method ($p > 0.01$). After covariate screening, the effects of albumin on CL_{linear} and weight on Q were retained in the final model. The main steps in the covariate model building from the base model to the final model are summarized in [Supplementary Materials Table S1](#).

The parameters of the final model are presented in [Table 3](#). The final model is listed below (Eq. 8):

$$\left\{ \begin{array}{l} CL_{linear} = 0.224 \times (\text{albumin}/44)^{-1.4} \times e^{\eta_{CL_t}} \\ Q = 0.433 \times (\text{weight}/61)^{1.33} \\ V_m = 2.86 \times e^{\eta_{V_m}} \\ K_m = 1.28 \\ V_1 = 3.08 \times e^{\eta_{V_1}} \\ V_2 = 2.88 \end{array} \right. \quad (\text{Eq. 8})$$

CL_{linear} decreases with albumin, and a decrease from albumin 50 g/L to albumin 25 g/L is associated with a 10.3% decrease in CL_{linear} ; BSV was reduced from 57.0 to 50.8% for CL_{linear} , indicating 10.8% of the BSV in CL_{linear} was explained by albumin; Q exhibits a linear correlation with weight.

The shrinkages of both BSV and residual variability were less than 30%, which indicates a reliable estimate of the individual empirical Bayes PK parameter ([Table 3](#)).

3.3 Model Evaluation

The goodness-of-fit for the final model ([Figure. 2](#)) showed a good agreement between observed and predicted values. The scatterplots of DV vs. PRED and DV vs. IPRED showed random scatter around the identity line, indicating the absence of systematic bias.

A non-parametric bootstrap with 1000 replicates was performed for the final model, with 915 of the replicates successfully presenting the minimization step. The

288 final model parameters and bootstrap results are presented in [Table 3](#). Overall, the
289 population estimates for the final model were close to the median of the bootstrap
290 replicates and were within the 2.5 – 97.5 percentiles obtained from the bootstrap
291 analysis. The precision of these parameter estimates was also satisfactory. The 95%
292 CIs did not contain any null values for any parameters.

293 The VPC showed that the median and 95% CI of the observed data were in line
294 with those from the simulation-based predictions from the model for all strata ([Figure.](#)
295 [3](#)).

296 **3.4 Simulations for Dosing Regimens**

297 Summary statistics for the observed camrelizumab exposures across the 200 mg
298 and 3 mg/kg Q2W are presented in [Table 4](#). The 2.5% – 97.5% of $C_{\text{average,ss}}$ for 3
299 mg/kg Q2W are from 12.81 to 113.87 $\mu\text{g/mL}$, which are similar to 200 mg Q2W
300 (15.28-112.08 $\mu\text{g/mL}$). The median $C_{\text{max,ss}}$, $C_{\text{min,ss}}$, and $C_{\text{average,ss}}$ values for 200 mg
301 Q2W are higher than those for 3 mg/kg Q2W.

302

303 **4 Discussion**

304 This is the first study to report a population PK model of camrelizumab in
 305 subjects with advanced melanoma, advanced solid tumors, and relapsed or refractory
 306 classical Hodgkin lymphoma. Camrelizumab PK were well described using a
 307 two-compartment model with parallel first-order and Michaelis–Menten CL from the
 308 central compartment.

309 The final model is in line with known characteristics of antibody PK, where the
 310 nonlinear pathway is thought to be related to clearance of the mAb via saturable
 311 target-mediated mechanisms (such as receptor-mediated endocytosis), while the linear
 312 component represents clearance pathways that are not saturable at therapeutic mAb
 313 concentrations (such as Fc-mediated elimination)¹⁸. The Michaelis–Menten constant
 314 in the model is 1.38 µg/mL, indicating that at low camrelizumab concentrations
 315 (<1.38 µg/mL), target-mediated elimination contributes a significant portion of the
 316 total CL. With increasing camrelizumab concentrations, the CL decreases
 317 dramatically as the target-mediated elimination pathway becomes saturated. When
 318 above the median of simulated concentration of 200 mg Q2W, the CL approaches that
 319 of the first-order process, and the contribution from the nonlinear pathway becomes
 320 negligible.

321 Our study also showed that camrelizumab CL decreased with increasing albumin
 322 level. The impact of albumin on PK of mAbs has been previously reported for
 323 infliximab, bevacizumab, ustekinumab, and pertuzumab.¹⁹ Because albumin and IgG
 324 share the same Fc receptor salvaging pathway, Fc receptor also binds and protects
 325 albumin from intracellular catabolism, thereby playing an important role in the
 326 homeostasis of both IgG and albumin.¹⁰ A higher albumin concentration could be an
 327 indicator of an increased number of Fc receptor s and a related reduction in the rate of
 328 camrelizumab elimination.²⁰ Although albumin had a statistically significant impact
 329 on CL_{linear}, simulation analyses demonstrated that the magnitude of its effect on
 330 camrelizumab exposure was limited (Figure 4). As albumin levels increased from 20

331 to 50 g/L, the median $C_{\min,ss}$ increased from 61 to 78 $\mu\text{g/mL}$, which are comparable to
 332 the 10 – 90% percentiles of the $C_{\min,ss}$ (39 to 123 $\mu\text{g/mL}$). Therefore, a dose
 333 adjustment for albumin is not warranted.

334 Therapeutic mAb dosing is usually based on body weight²¹. However, this dosing
 335 paradigm has recently been re-evaluated because of the wide dose range for the
 336 therapeutic efficacy and tolerability for camrelizumab. Flat dose is considered and
 337 applied in the clinical settings due to increased convenience, elimination of wastage,
 338 improved safety, and improved compliance.⁹ Our study showed that only weight has
 339 an impact on Q of camrelizumab, and it has little effect on camrelizumab exposure.
 340 Meanwhile, the mean exposure profile for the 200 mg flat dose is essentially similar
 341 to that of the 3 mg/kg profile. Although patients with increased weight had lower
 342 exposures with the 200 mg flat dose compared to the 3 mg/kg regimen, the
 343 distribution of exposures obtained in these patients was within the range of exposures
 344 from the prior clinical reports.²² It was demonstrated in this study that both
 345 weight-based and fixed flat dosing are appropriate for camrelizumab, with neither
 346 regimen providing a PK advantage over the other.

347 There are several limitations in this study. The study was based solely on
 348 dose-exposure analysis and all patients were from China. Whether the results could be
 349 applied to population of North American and European countries, remains to be
 350 elucidated. In addition, comprehensive safety and efficacy data were lacking. Further
 351 research including an exposure-response study is needed to inform clinical dosing
 352 strategy.

353 **5 Conclusions**

354 In this study, a population PK model of camrelizumab was developed to quantify
 355 the impact of patient characteristics on PK. The PK of camrelizumab were described
 356 by a two compartment model with parallel linear and nonlinear clearance from the
 357 central compartment. Although albumin levels and patient weight had statistically
 358 significant impacts on the PK of camrelizumab, the magnitude was limited and dose

adjustments were not required. Doses of 200 mg and 3 mg/kg provided similar exposure distributions with no advantage to either dosing approach with respect to controlling PK variability.

Acknowledgements:

We thank Wei-wei Wang, Qing Yang and Xiao-jing Zhang from Jiangsu Hengrui Medicine Co. Ltd for critical review of the manuscript. We would like to thank Editage (www.editage.cn) for English language editing.

CRediT author statement

Chen-yu Wang: Methodology, Software, Formal analysis, Validation, Visualization, Writing – Original Draft, Writing - Review & Editing. **Chang-cheng Sheng:** Methodology, Software, Formal analysis, Writing - Review & Editing. **Guang-li Ma:** Methodology, Data Curation, Supervision, Writing - Review & Editing. **Da Xu:** Data Curation, Writing - Review & Editing. **Xiao-qin Liu:** Software, Formal analysis. **Yu-ya Wang:** Data Curation. **Li Zhang:** Data Curation. **Chuan-liang Cui:** Data Curation. **Bing-he Xu:** Data Curation. **Yu-qin Song:** Data Curation. **Jun Zhu:** Data Curation. **Zheng Jiao:** Conceptualization, Methodology, Writing – Original Draft, Writing - Review & Editing.

Conflicts of interest

This study was sponsored by Jiangsu Hengrui Medicine Co. Ltd. Guang-li Ma, Da Xu and Yu-ya Wang are employees of Jiangsu Hengrui Medicine Co. Ltd.

Reference

1. Huang J, Xu B, Mo H, Zhang W, Chen X, Wu D, et al. Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. *Clin Cancer Res* 2018; 24: 1296-304.
2. Markham A, Keam SJ. Camrelizumab: First Global Approval. *Drugs* 2019; 79: 1355-61.
3. AiRuiKa®. [package insert], Lianyungang, China. *Jiangsu Hengrui Medicine Co Ltd* 2019.
4. Song Y, Wu J, Chen X, Lin T, Cao J, Liu Y, et al. A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. *Clin Cancer Res* 2019; 25: 7363-69.
5. Huang J, Mo H, Zhang W, Chen X, Qu D, Wang X, et al. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. *Cancer* 2019; 125: 742-49.
6. Zhang Z, Zhou Y, Hu K, Li Z, Wang Z, Huang Y. Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib. *Dig Liver Dis* 2019; 51: 1488-90.
7. Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. *The Lancet Oncology* 2018; 19: 1338-50.
8. Lickliter JD, Gan HK, Voskoboinik M, Arulananda S, Gao B, Nagrial A, et al. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. *Drug Des Devel Ther* 2020; 14: 1177-89.
9. Mo H, Huang J, Xu J, Chen X, Wu D, Qu D, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. *Br J Cancer* 2018; 119: 538-45.
10. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. *Clin Pharmacokinet* 2010; 49: 633-59.
11. Lv JW, Li JY, Luo LN, Wang ZX, Chen YP. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials. *Journal for immunotherapy of cancer* 2019; 7: 159.
12. Wang Y, Booth B, Rahman A, Kim G, Huang SM, Zineh I. Toward greater insights on pharmacokinetics and exposure-response relationships for therapeutic biologics in oncology drug development. *Clin Pharmacol Ther* 2017; 101: 582-84.
13. Czarkowski M. [Helsinki Declaration--next version]. *Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego* 2014; 36: 295-7.
14. Fajsz C, Endrenyi L. New linear plots for the separate estimation of

- 421 Michaelis-Menten parameters. *FEBS Lett* 1974; 44: 240-6.
- 422 15. Ahamadi M, Largajolli A, Diderichsen PM, de Greef R, Kerbusch T, Witjes H, et
423 al. Operating characteristics of stepwise covariate selection in pharmacometric
424 modeling. *J Pharmacokinet Pharmacodyn* 2019; 46: 273-85.
- 425 16. Donohue MC, Overholser R, Xu R, Vaida F. Conditional Akaike information
426 under generalized linear and proportional hazards mixed models. *Biometrika*
427 2011; 98: 685-700.
- 428 17. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV. Model
429 appropriateness and population pharmacokinetic modeling. *J Clin Pharmacol*
430 2003; 43: 610-23.
- 431 18. Bensalem A, Ternant D. Pharmacokinetic Variability of Therapeutic Antibodies
432 in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling
433 Publications. *Clinical pharmacokinetics* 2020.
- 434 19. Baverel PG, Dubois VFS, Jin CY, Zheng Y, Song X, Jin X, et al. Population
435 Pharmacokinetics of Durvalumab in Cancer Patients and Association With
436 Longitudinal Biomarkers of Disease Status. *Clin Pharmacol Ther* 2018; 103:
437 631-42.
- 438 20. Cho J, Park J, Tae G, Jin MS, Kwon I. The Minimal Effect of Linker Length for
439 Fatty Acid Conjugation to a Small Protein on the Serum Half-Life Extension.
440 *Biomedicines* 2020; 8.
- 441 21. Temrikar ZH, Suryawanshi S, Meibohm B. Pharmacokinetics and Clinical
442 Pharmacology of Monoclonal Antibodies in Pediatric Patients. *Paediatr Drugs*
443 2020; 22: 199-216.
- 444 22. Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D, et al.
445 Evaluation of dosing strategy for pembrolizumab for oncology indications. *J*
446 *Immunother Cancer* 2017; 5: 43.

447

Tables

Table 1. Summary of clinical studies used in this population-pharmacokinetic modeling study.

Study	Dosing regimen	Indication	Number of subjects	Number of PK Samples	Scheduled PK time points
SHR-1210-101	1mg/kg, 3mg/kg, 10mg/kg and 200mg, Q2W	Advanced solid tumors	49	1140	Cycle 1: 30 min before and 0.1, 2, 6, 24, 48, 168, 336, 504 h after end of infusion on day 1 Cycle 2 and subsequent cycles: 30 min before and 0.1 h after end of infusion on day 1 and 15.
SHR-1210-102	60mg, 200mg and 400mg, Q2W	Advanced Melanoma	36	986	Same as above
SHR-1210-103	60mg, 200mg and 400mg, Q2W	Advanced solid tumors	36	1052	Same as above
SHR-1210-II-204	200mg, Q2W	Relapsed or refractory classical Hodgkin lymphoma	12	120	Cycle 1: 30 min before and 0.1, 2 h after end of infusion Cycle 2, Cycle 4 and Cycle 6: 30 min before and 0.1 h after end of infusion

Table 2. Baseline demographic and disease characteristics of 133 patients.

Covariate	SHR-1210-101	SHR-1210-102	SHR-1210-103	SHR-1210-II-204	Total
Number of patients	49 (36.8%)	36 (27.1%)	36 (27.1%)	12 (9.0%)	133 (100%)
Number of PK Samples	1140 (34.6%)	986 (29.9%)	1052 (31.9%)	120 (3.6%)	3298 (100%)
Age (years)	47 (23 - 69)	52 (29 - 68)	54.5 (35 - 65)	28.5 (21 - 50)	50 (21 - 69)
Weight (kg)	56.5 (36.8 - 72.1)	64 (41 - 90)	65.5 (47 - 91)	63 (42 - 86)	61 (36.8 - 91)
Sex					
Male	37 (75.5%)	17 (47.2%)	28 (77.8%)	6 (50%)	88 (66.2%)
Female	12 (24.5%)	19 (52.8%)	8 (22.2%)	6 (50%)	45 (33.8%)
Race					
Han	49 (100%)	34 (94.4%)	34 (94.4%)	11 (91.7%)	128 (96.2%)
Others	0 (100%)	2 (5.6%)	2 (5.6%)	1 (8.3%)	5 (3.8%)
Creatinine clearance (mL/min)	89.07 (51.5 - 159.0)	108.33 (52.8 - 178.7)	101.1 (61.3 - 160.9)	136.93 (110.7 - 210.8)	100.69 (51.5 - 210.8)
Aspartate aminotransferase (U/L)	15.4 (6.4 - 72.8)	23.5 (13 - 82)	21 (12 - 49)	19 (13 - 38)	21.7 (8 - 115.4)
Alanine aminotransferase (U/L)	22.9 (8 - 115.4)	16 (5 - 88)	15 (7 - 55)	13 (5 - 54)	15 (5 - 88)
Total bilirubin (umol/L)	8.3 (5.1 - 20.6)	11.45 (5.9 - 24.1)	9.8 (4.9 - 22.3)	11.25 (8.4 - 24.2)	9.7 (4.9 - 24.2)
Albumin (g/L)	43.2 (29.7 - 50.4)	45.3 (32.7 - 52.5)	44.1 (38.2 - 50.2)	41.7 (35.3 - 48.1)	44 (29.7 - 52.5)
Tumor					
Nasopharyngeal carcinoma	31 (63.3%)	/	3 (8.3%)	/	34 (25.6%)
Lung cancer	18 (36.7%)	/	3 (8.3%)	/	21 (15.8%)
Melanoma	/	36 (100%)	/	/	36 (27.1%)
Esophageal cancer	/	/	14 (38.9%)	/	14 (10.1%)
Gastric cancer	/	/	5 (13.9%)	/	5 (3.8%)
Classical Hodgkin lymphoma	/	/	/	12 (100%)	12 (9.0%)
Others	/	/	11 (30.6%)	/	11 (8.2%)
Co-administration					
Monotherapy	48 (98.0%)	33 (91.7%)	36 (100%)	12 (100%)	129 (97.0%)
Combination therapy	1 (2%)	3 (8.3%)	/	/	4 (3%)

Parameters	Base model		Final model		
	Parameter estimates (%CV)	Shrinkage (%)	Parameter estimates (%CV)	Shrinkage (%)	Bootstrap Median (2.5% - 97.5%)
CL _{linear} (L/day)	0.242 (2.7)	/	0.231 (6.1)	/	0.23 (0.20 - 0.26)
V _m (mg/day)	2.86 (3)	/	2.94 (7.5)	/	3.00 (2.26 - 3.71)
K _m (mg/L)	1.28 (1.4)	/	1.38 (13)	/	1.40 (0.91 - 2.76)
V ₁ (L)	3.08 (2.7)	/	3.07 (3.7)	/	3.08 (2.77 - 3.33)
Q (L/day)	0.385 (3.8)	/	0.414 (6.7)	/	0.41 (0.34 - 0.51)

Table 3. Population-pharmacokinetic parameter estimates and bootstrap evaluation.

V ₂ (L)	2.88 (2.8)	/	2.9 (3.6)	/	2.91 (2.35 - 3.35)
albumin on CL _{linear}	/	/	-1.98 (24.2)	/	-1.93 (-2.94 - -0.89)
weight on Q	/	/	1.22 (26.9)	/	1.18 (0.31 - 2.28)
Between subject variability					
CL _{linear} (%)	57.0 (8.6)	11.6	50.8 (9)	13	50.2 (32.7 - 68.9)
V _m (%)	48.3 (8.7)	17.5	49.5 (9)	18	47.8 (29.4 - 70.9)
V ₁ (%)	40.2 (6.7)	3	40.7 (7)	3	39.0 (17.0 - 70.68)
Residual variability					
proportional error (%)	29.4 (1.7)	4.5	29.3 (3)	4.5	28.9 (23.8 - 33.9)
additive error (mg/L)	0.0812 (3.2)	4.5	0.0827 (32)	4.5	0.0823 (0.0293-0.112)

CL_{linear}, clearance of linear elimination; V_m, maximum elimination rate; K_m, Michaelis–Menten constant; V₁, distribution volume of central compartment; Q, inter-compartmental clearance; V₂, distribution volume of peripheral compartment;

Table 4. Predicted summary statistics of camrelizumab exposure metrics.

	3mg/kg every 2 weeks		200mg every 2 weeks	
	Median	2.5%-97.5%	Median	2.5%-97.5%
$C_{\max, ss}$ (µg/mL)	89.55	39.27-195.41	96.40	47.26-190.36
$C_{\min, ss}$ (µg/mL)	23.11	1.22-92.70	26.13	1.78-90.96
$C_{\text{average}, ss}$ (µg/mL)*	41.27	12.81-113.87	45.48	15.28-112.08

$C_{\max, ss}$, steady-state peak concentration; $C_{\min, ss}$, steady-state trough concentration; $C_{\text{average}, ss}$, steady-state average concentration.

$$*C_{\text{average}, ss} = \frac{AUC_{ss} (mg \times weeks / L)}{\text{dosing interval (weeks)}}$$

Figure legends

Figure 1. Model Structure.

k_0 , infusion rate; k_{23} , elimination rate from central compartment to peripheral compartment; k_{32} , elimination rate from peripheral compartment to central compartment; k_{linear} , linear elimination rate; $\text{CL}_{\text{linear}}$, clearance of linear elimination; Q , inter-compartmental clearance; V_1 , apparent distribution volume of central compartment; V_2 , apparent distribution volume of peripheral compartment; $k_{\text{nonlinear}}$, nonlinear elimination rate; C_1 , concentration of central compartment; V_m , maximum elimination rate; K_m , Michaelis–Menten constant.

Figure 2. Goodness-of-fit plots of the final population-pharmacokinetic model.

The red line represents the locally weighted scatterplot smoothing line.

Figure 3. Visual predictive check.

Circles represent observed data. Lines represent the 5% (dashed), 50% (solid), and 95% (dashed) percentiles of the observed data. Shaded areas represent nonparametric 95% confidence intervals about the 5% (light blue), 50% (light red), and 95% (light blue) percentiles for the corresponding model-predicted percentiles.

Figure 4. Sensitivity plots comparing effect of covariates on steady state exposure.

(a) C_{min} ; (b) C_{max} ; (c) C_{average} . Vertical reference lines represent typical steady-state exposure value of a 62-kg patient with albumin of 44 g/L receiving 200 mg of camrelizumab every 2 weeks. The top bars in each plot represent the 5% – 95% exposure values across the entire population. The labels at each of the lower bars indicate range of the covariate values. The length of each bar describes the impact of that particular covariate on the observed PK parameter.